Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Public News Service on MSN
Cancer research continues despite funding cuts
The American Cancer Society estimates more than 20,000 Arkansans will be diagnosed with some form of cancer this year. Cancer ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...
Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...
However, data also showed that vegetarians had a higher risk of esophageal cancer and vegans had a higher risk of colorectal ...
Nearly 143,000 Hoosiers will die from cancer this year, according to data from the Indiana Department of Health and the ...
Prostate cancer kills thousands of Americans each year but new research suggests men can drastically lower their risk ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results